Johnson & Johnson has shown some recovery in its stock price which was backed by a solid result across its business segments. In spite of the significant inflationary impacts on the input costs, the company accelerated operational growth across every segment and delivered an all-around beat. Pharmaceutical growth was determined by robust commercial execution and access that enabled Johnson & Johnson to continue to deliver growth in operational growth. The growth of the company was driven by Erle ....
